Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK

OAK, the first randomized Ph III study of atezolizumab (atezo; anti-PD-L1), demonstrated a superior survival benefit with atezo vs. docetaxel (doc) in NSCLC patients (pts) who had failed prior platinum therapy (HR 0.73; 95% CI: 0.62, 0.87). This analysis evaluates the benefit of atezo in pts with and without irAEs from the primary efficacy population (n = 850) of OAK. Safety data are reported separately.